IBUDONE 5/200

Compare IBUDONE 5/200  to:
Compare
Compare

Generic Name for IBUDONE 5/200

Hydrocodone bitartrate 5mg, ibuprofen 200mg; tabs.

Legal Classification:

CIII

Pharmacological Class for IBUDONE 5/200

Opioid + NSAID.

Manufacturer of IBUDONE 5/200

Poly Pharmaceuticals

Indications for IBUDONE 5/200

Short term (generally <10 days) management of acute pain.

Adult dose for IBUDONE 5/200

Individualize; use lowest effective dose for shortest time. ≥16yrs: 1 tab every 4–6 hours as needed; max 5 tabs/day.

Children's dosing for IBUDONE 5/200

<16yrs: not recommended.

Also:

Contraindications for IBUDONE 5/200

Aspirin allergy. Coronary artery bypass graft surgery. 3rd trimester pregnancy.

Precautions for IBUDONE 5/200

Advanced renal disease: not recommended. Head injury. Increased intracranial pressure. Acute abdomen. Peptic ulcer. History of upper GI disease. Impaired renal, hepatic, thyroid, pulmonary, or adrenocortical function. GI or GU obstruction. Asthma. Edema. Hypertension. Heart failure. Bleeding disorders. Monitor BP, blood, and hepatic and renal function. Dehydration. Post-op (may suppress cough reflex). Drug abusers. Discontinue if hepatic dysfunction occurs. Elderly. Debilitated. Pregnancy (Cat.C). Labor & delivery, nursing mothers: not recommended.

Interactions for IBUDONE 5/200

See Contraindications. Avoid aspirin. Alcohol, other CNS depressants potentiated. May potentiate, or be potentiated by, MAOIs (not recommended) or tricyclic antidepressants, skeletal muscle relaxants. Increases serum lithium levels. May reduce efficacy of, and increase risk of renal failure with, ACEIs, diuretics. May increase bleeding with anticoagulants. Paralytic ileus may occur with anticholinergics. May increase lithium, methotrexate toxicity. Corticosteroids increase risk of GI bleed.

Adverse Reactions for IBUDONE 5/200

Headache, CNS depression, dizziness, GI upset/bleed, constipation, rash (discontinue if occurs), respiratory depression, anemia, mood changes, confusion, anaphylaxis; aseptic meningitis (rare); others. See literature re: risk of cardiovascular events.

How is IBUDONE 5/200 supplied?

Tabs—100

Related Disease:

Pain, general~narcotics

Related Resources

Exalgo approved for moderate to severe pain

March 02, 2010

The FDA has approved Exalgo (hydromorphone HCl extended-release tablets, from Covidien) for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

Phase 3 study of MoxDuo IR for pain management

February 10, 2010

QRxPharma Limited announced initiation of a second Phase 3 registration trial (Study 009) to evaluate its MoxDuo IR (morphine and oxycodone) product for the management of moderate to severe pain in patients who have undergone total knee replacement surgery.

FDA-approved morphine sulfate oral solution 100mg/5mL available

January 27, 2010

Roxane Laboratories announced that the New Drug Application (NDA) for high concentrate morphine sulfate oral solution 100mg/5mL (20mg/mL) has been approved by the FDA.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

NDA submitted for extended-release tapentadol tablets for chronic pain

December 02, 2009

Johnson & Johnson and its subsidiaries, PriCara and Ortho-McNeil-Janssen, announced that they have submitted a New Drug Application (NDA) to the FDA for tapentadol extended release (ER) tablets for the management of moderate to severe chronic pain in patients ≥18 years of age.